Welcome to our dedicated page for Tg Therapeutics news (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on Tg Therapeutics stock.
TG Therapeutics develops and commercializes therapies for B-cell diseases, with news centered on BRIUMVI (ublituximab-xiiy), its anti-CD20 monoclonal antibody for adult patients with relapsing forms of multiple sclerosis. Company updates commonly cover U.S. net product revenue, global revenue targets, commercial demand, and international commercialization economics tied to BRIUMVI.
Recurring developments also include clinical and real-world data for BRIUMVI in relapsing multiple sclerosis, presentations and publications from multiple sclerosis studies, and development work on a subcutaneous formulation. Corporate news includes financing arrangements, share repurchase authorization updates, operating-expense guidance, and business outlook commentary alongside quarterly and annual results.
TG Therapeutics will host a fireside chat on December 1, 2020, at 10:05 AM ET, featuring Executive Chairman and CEO Michael S. Weiss. This event is part of the 3rd Annual Evercore ISI HealthCONx Conference. Investors can access the live webcast on the company’s website.
The company is advancing treatments for B-cell malignancies and autoimmune diseases, focusing on investigational drugs ublituximab and umbralisib, known as “U2.” Umbralisib is currently under FDA review for treating specific lymphomas.
TG Therapeutics, Inc. (NASDAQ: TGTX) announced that Michael S. Weiss, Executive Chairman and CEO, will participate in a fireside chat on November 17, 2020, at 2:20 PM ET during the Jefferies Virtual London Healthcare Conference. A live webcast will be accessible on the company’s Events page. The company focuses on developing innovative treatments for B-cell malignancies and autoimmune diseases, with investigational compounds like ublituximab and umbralisib in late-stage clinical development.
TG Therapeutics (TGTX) reported its Q3 2020 financial results, highlighting significant advancements in its clinical trials. The UNITY-CLL Phase 3 trial achieved its primary endpoint, indicating improved progression-free survival. The NDA for umbralisib was accepted for MZL and FL, with PDUFA goal dates set for February and June 2021. The company boasts a proforma cash position of $325 million and plans to submit a BLA/NDA for U2 for CLL. R&D expenses decreased, while net loss widened to $87.2 million. A focus remains on upcoming ASH 2020 presentations and remaining 2020 milestones.
TG Therapeutics (NASDAQ: TGTX) announced promising results from its UNITY-CLL and UNITY-NHL trials, highlighting the efficacy of the U2 combination therapy in chronic lymphocytic leukemia (CLL). The U2 therapy showed a significant increase in progression-free survival (PFS) compared to obinutuzumab plus chlorambucil (HR=0.54, p0.0001). Additionally, umbralisib monotherapy displayed a 49.3% overall response rate (ORR) in relapsed/refractory marginal zone lymphoma. The company will discuss these findings in a conference call on November 5, 2020.
TG Therapeutics has announced the acceptance of four abstracts for presentation at the 62nd American Society of Hematology (ASH) meeting, scheduled for December 5-8, 2020. The abstracts highlight key data from registration-directed trials of ublituximab and umbralisib, including results from the UNITY-CLL Phase 3 trial. An NDA for umbralisib monotherapy is under review, with a BLA/NDA submission for the U2 combination planned in coming months. A Zoom conference call with trial investigators will occur on November 5, 2020, at 8:45 AM ET.
TG Therapeutics, on October 21, 2020, announced that the FDA granted Fast Track Designation for its U2 combination therapy, ublituximab and umbralisib, aimed at treating chronic lymphocytic leukemia (CLL). This designation facilitates expedited development and regulatory review, addressing significant unmet medical needs for CLL patients. The Fast Track application was backed by positive data from the UNITY-CLL Phase 3 trial, which met its primary endpoint of progression-free survival. Data presentation from this trial is expected later this year, supporting regulatory submission.
TG Therapeutics (NASDAQ: TGTX) will participate in two virtual investor conferences. CEO Michael S. Weiss is scheduled for fireside chats at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 1:30 PM ET, and at the Cantor Fitzgerald Global Healthcare Conference on September 16, 2020, at 10:40 AM ET. Live webcasts of the presentations will be available on the company’s website. TG Therapeutics focuses on developing treatments for B-cell malignancies and autoimmune diseases, with two investigational compounds currently in late-stage clinical development.
TG Therapeutics, Inc. (NASDAQ: TGTX) announced that the FDA has accepted its New Drug Application for umbralisib, a dual inhibitor for marginal zone lymphoma (MZL) and follicular lymphoma (FL). The FDA granted the MZL indication Breakthrough Therapy Designation and set a PDUFA goal date of February 15, 2021, while the FL indication has a goal date of June 15, 2021. The NDA is based on UNITY-NHL Phase 2b trial data, which showed an overall response rate (ORR) of 40-50% for both MZL and FL cohorts. The acceptance is a significant step towards providing treatment options for patients with B-cell malignancies.
TG Therapeutics (TGTX) announced the publication of preclinical data on umbralisib, its dual PI3K-delta and CK1-epsilon inhibitor, in Blood Advances. CEO Michael S. Weiss highlighted the encouraging safety profile observed in clinical trials, suggesting a differentiated safety mechanism due to umbralisib’s unique immunomodulatory effects. The study revealed that umbralisib maintained Treg function better than other inhibitors, with significant implications for treating CLL. The data supports the ongoing Phase 3 trials for both umbralisib and ublituximab in hematological malignancies.
TG Therapeutics announced that Executive Chairman and CEO Michael S. Weiss will present at the Raymond James 2020 Human Health Innovation Conference on June 18, 2020, at 3:40 PM ET. The conference will be held virtually, and a live webcast of the presentation can be accessed via the Company's website.
TG Therapeutics focuses on developing treatments for B-cell malignancies and autoimmune diseases. Its key therapies include ublituximab and umbralisib, currently in Phase 3 clinical trials.